Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000902012 | SCV001046411 | likely benign | not provided | 2019-12-31 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002479036 | SCV002802027 | likely benign | McCune-Albright syndrome; Pseudohypoparathyroidism type 1C; Pseudohypoparathyroidism type 1B; Pseudopseudohypoparathyroidism; Progressive osseous heteroplasia; Pituitary adenoma 3, multiple types; ACTH-independent macronodular adrenal hyperplasia 1; Pseudohypoparathyroidism type I A | 2021-09-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004735876 | SCV005350122 | uncertain significance | GNAS-related disorder | 2024-08-26 | no assertion criteria provided | clinical testing | The GNAS c.958G>A variant is predicted to result in the amino acid substitution p.Asp320Asn. This variant occurs in the pre-coding region of the primary GNAS transcript (NM_000516:c.-37504G>A). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.034% of alleles in individuals of Latino descent in gnomAD. Although we suspect that this variant is benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |